Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages (PREMI)

Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages, PREMI Trial

Recurrent miscarriages (RM) affects 3% of all fertile couples, but remains unexplained in most cases, limiting therapeutic options. Possibly the maternal immune system plays a role in recurrent miscarriage. Prednisolone suppresses the immune system and might enable development of normal pregnancy.

In this randomized controlled clinical trial the investigators will study the effect of prednisolone on the live birth rate in patients with RM. Secondary, the tolerability and safety for mother and child and the cost-effectiveness is investigated.

In the study one group of pregnant women with RM and gestational age <7 weeks will receive prednisolone, the other group will receive a placebo. Total use of the medicine during this study is 8 weeks, further care during the study is routinely antenatal care. Subjects will be asked to fill in 4 short questionnaires and will have contact with a research nurse at different time points to gain information on the course of the pregnancy and possible side effects.

Results of the study will be implemented in (inter) national guidelines, to effect everyday practice.

Study Overview

• Status: Recruiting
• Conditions: Miscarriage; Recurrent Miscarriage; Fertility Disorders; Recurrent Pregnancy Loss; Habitual Abortion
• Intervention / Treatment: Drug: Prednisolone; Drug: Placebo

Detailed Description

Rationale:

Recurrent miscarriage (RM) is defined as 2 or more spontaneous miscarriages. It affects 3% of all fertile couples and in less than 50% an underlying cause may be identified. Thus far, none of the therapies tested in women with unexplained RM showed improvement of the live birth rate (LBR).

As the fetus is a semi-allograft, which escapes maternal immune rejection in normal pregnancy, many studies proposed the involvement of immunological mechanism in RM.

Glucocorticoids could have an effect on these mechanisms. Indeed, a recent meta-analysis has shown a beneficial effect on live birth rate for treatment with prednisolone therapy (RR 1.58, 95% CI 1.23-2.02). The included trials however were inadequately powered, differed in inclusion criteria or contained co-intervention with heparin and aspirin. In addition, most patients were selected based on the natural killer cell density in prior uterine biopsy, though this has not yet proven to be a valid biomarker.

Objectives:

To assess the effectiveness of prednisolone administration, as compared to placebo, on the LBR in an unselected population of women with unexplained RM.

Secondary, the effectiveness of prednisolone on the LBR in various subgroups, the tolerability and safety of prednisolone, the cost-effectiveness and the effect on immune cell levels is studied.

Main study parameters/endpoints:

Primary outcome: live birth rate Secondary outcome: miscarriage rate, ongoing pregnancy rate, adverse events (including side effects and pregnancy complications), decidual immune cell level and direct costs.

Trial design:

Randomized double-blind, placebo controlled multi-center clinical trial. Follow up period ends 3 months after delivery (12 months after randomization).

Trial population:

Women with unexplained recurrent miscarriage, including at least 2 miscarriages, aged 18- 39 years are recruited in a new pregnancy with AD <7 weeks from 10 participating centers in the Netherlands (Coordinating center Leiden University Medical Centre, LUMC).

Diagnosis unexplained recurrent miscarriages is based on latest ESHRE guideline.

Intervention:

After a complete diagnostic work-up, eligible women will be asked to collect a sample of menstrual blood. Patients are then randomized for prednisolone or placebo in a subsequent pregnancy. Women are randomly assigned in a 1:1 ratio to prednisolone tablets (20 mg daily for 6 weeks, 10 mg daily for 1 week, 5 mg daily for 1 week) or identical placebo tablets.

The participants will then receive prenatal visits according to standard care with their own treating physician. All patients will be asked to fill in questionnaires at randomization, and 3, 6 and 12 months after randomization. In a subgroup of patients participating in the LUMC and Radboud MC, additional analyses will be performed, aimed at elucidating the effect of prednisolone on level of different immune cell populations in miscarriage tissue or placenta.

Ethical considerations relating to the clinical trial including the expected benefit to the individual subject or group of patients represented by the trial subjects as well as the nature and extent of burden and risks:

In the PREMI study the investigators will evaluate the effect of prednisolone on the live birth rate in patients with RM in a randomized, placebo-controlled trial. The risks and burden of participating in the trial are estimated as small. The risk of participation is the risk of prednisolone use; substantial evidence exists that prednisolone in this dosage and usage in first trimester is safe for mother and fetus.

Patients may however experience barriers for participation in this study, due to the possible assignment to the placebo-arm (with a possible nil effect on pregnancy outcome), as well as potential side effects. Considering the latter, in a previous feasibility trial no side effects were severe enough for women to stop taking medication. Moreover, to establish the most valid results as possible, there is no other solid manner to answer this research question than by conducting a well-designed double blinded placebo-controlled RCT.

• Study Type: Interventional
• Enrollment (Estimated): 490
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Eileen Lashley, PhD; Phone Number: 0031-715263362; Email: e.e.l.o.lashley@lumc.nl

Study Locations

• Netherlands
  • Zuid-Holland
    • Leiden, Zuid-Holland, Netherlands, 233ZA
      • Recruiting
      • Leiden University Medical Center
      • Contact: Yentl Bequet, MD; Phone Number: +31 652334371; Email: y.l.b.n.bequet@lumc.nl
      • Contact: Lisa Lashley, MD, PhD, MsC; Email: e.e.l.o.lashley@lumc.nl
      • Principal Investigator: Eileen Lashley, MD, PhD
      • Principal Investigator: Marie-Louise van der Hoorn, MD, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

• Unexplained recurrent pregnancy loss: defined as the loss of ≥2 pregnancies, without any known cause for RM (parental chromosomal abnormalities, uterine anomalies, acquired or hereditary thrombophilia, endocrine diseases (such as hypothyroidism or diabetes)).

• The miscarriages include:

  • all consecutive or non-consecutive pregnancy losses before the 24th week of gestation verified by ultrasonography or uterine curettage and histology
  • non-visualized pregnancies (including biochemical pregnancy losses and/or resolved and treated pregnancies of unknown location), verified by positive urine or serum hCG Ectopic and molar pregnancies are not included
• Age 18 - 39 years at randomization (likelihood of miscarriages due to chromosomal aberrations is higher when age > 39 years. Such miscarriages are unlikely to be pre-vented by prednisolone therapy)
• Conception confirmed by urinary pregnancy test, with estimated gestational age ≤ 7weeks
• Willing and able to give informed consent in English or Dutch (IC)

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

• Any of the following diagnosis for the recurrent miscarriages

  • Antiphospholipid syndrome (lupus anticoagulant and/ or anticardiolipin anti-bodies and/or beta-2 glycoprotein [IgG or IgM)
  • Congenital uterine abnormalities (as assessed by 2D or 3d ultrasound, hys-terosonography, hysterosalpingogram or hysteroscopy)
  • Abnormal parental karyotype
• Instable or exacerbation of auto-immune diseases such as diabetes, thyroid disease, inflammatory bowel diseases or SLE
• Inability to conceive within 1 year of recruitment
• Current treatment with systemic prednisolone or other immune suppressive medication (for any indication)
• Previous enrolment in the PREMI trial
• Enrolment in any other trial that studies the effectiveness of an intervention on RM

• Contraindications to prednisolone use:

  • Known allergy for prednisolone
  • Acute bacterial infection or parasite infection
  • Active COVID infection
  • Systemic sclerosis
  • Ulcus ventriculi or ulcus duodeni in medical history
  • Obesity with BMI >40

• Some drugs are known to interact with Prednisolone, and thus women on the following drugs are not eligible to take part in the PREMI trial:

  • Enzyme inducers, such as carbamazepine, fenobarbital, fenytoïne and ri-fampicine
  • CYP3A inhibitors, such as Cobicistat or Ritonavir
  • Cyclosporine
  • Digoxin
  • Vaccination (with inactivated virus or bacteria) during prednisolone use is possibly less effective

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Prednisolone; Prednisolone tablets (20 mg daily for 6 weeks, 10 mg daily for 1 week, 5 mg daily for 1 week)	Drug: Prednisolone; Prednisolone tablets (20 mg daily for 6 weeks, 10 mg daily for 1 week, 5 mg daily for 1 week) or identical placebo tablets for 8 weeks
Placebo Comparator: Placebo; Identical placebo tablets for 8 weeks	Drug: Placebo; Placebo identical to prednisolone tablets

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Live birth rate	Birth of a living child beyond 24 weeks	Within 24 months after eligibility

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ongoing pregnancy	Fetal heartbeat on ultrasound scan at 12 weeks	At +/- 12 weeks of pregnancy
Congenital abnormalities	Number of children born with congenital deformity (such as cleft palate)	At or short after birth, within 24 months after eligibility
Gestational age	Gestational age measured in weeks after conception until delivery	After birth, within 24 months after eligibility
Survival at 28 days of neonatal life	Is newborn still alive 28 days after birth	28 days postpartum
Adverse events	Side effect of steroids (eg: insomnia, mood changes, indigestion)	From start intervention until stop intervention (maximum of 7 weeks)
Pregnancy complications	Such as preeclampsia, pregnancy induced hypertension, HELLP and gestational diabetes	During pregnancy, maximum of 9 months
Direct and indirect costs	Cost directly and undirectly related to intervention in comparrison to standard care	After intervention, after a maximum of 24 months
Anxiety and depression	Anxiety and depression measured with questionnaire (HADS)	Measurement at start of pregnancy (randomisation), 3, 6 and 12 months after start
Quality of life (Health state)	Quality of life measured through questionnaire (EQ-5D-5L) mobility, self-care, usual activities, pain/discomfort and anxiety/depression.	Measurement at start of pregnancy (randomisation), 3, 6 and 12 months after start
Birthweight	Measured in kilograms at time of birth	At birth, within 24 months after eligibility
Productivity costs due to condition	Productivity loss and costs measured through questionnaire (iPCQ)	6 and 12 months after randomisation
Medical consumption	Medical consumptoin expressed in e.g. number of visits measured through questionnaire (iMCQ)	6 and 12 months after randomisation

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Level of immune cells post intervention	level of uNK cells, regulatory T cells and CD14+/CD163+ macrophages in placenta or miscarriage tissue	After miscarriage or delivery, within 24 months after eligibility

Collaborators and Investigators

• Sponsor: Leiden University Medical Center
• Collaborators: Radboud University Medical Center; Maastricht University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis Eindhoven; Onze Lieve Vrouwe Gasthuis; Academisch Ziekenhuis Groningen; Jeroen Bosch Ziekenhuis; Isala; Amphia Hospital; Haaglanden Medical Centre; Amsterdam University Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): January 29, 2024
• Primary Completion (Estimated): July 29, 2026
• Study Completion (Estimated): July 29, 2027

Study Registration Dates

• First Submitted: January 19, 2023
• First Submitted That Met QC Criteria: February 2, 2023
• First Posted (Actual): February 13, 2023

Study Record Updates

• Last Update Posted (Actual): January 31, 2024
• Last Update Submitted That Met QC Criteria: January 30, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: Recurrent miscarriage; prednisolone; Recurrent pregnancy loss
• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Recurrence; Abortion, Spontaneous; Abortion, Habitual; Physiological Effects of Drugs; Anti-Inflammatory Agents; Antineoplastic Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Prednisolone
• Other Study ID Numbers: LUMC-PREMI

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Possibly various covariates among women with RM contribute to the effect of prednisolone on the live birth rate. To further study the effect of prednisolone in predefined subgroups we aim to conduct a individual participant data meta-analysis.

These subgroups include groups defined on female age, number of previous miscarriages, antinuclear antibodies positivity and TPO antibodies positivity

• IPD Sharing Time Frame: After results have been published in a manuscript.
• IPD Sharing Access Criteria: If informed consent of participants is available, individual data on above mentioned co-variates will be shared for IPD meta-analysis. Sharing will be done after publication and will be available up to 5 years after study has ended. Study protocol will be available too. Data will only be shared with researchers with a methodologically sound proposal directed to e.e.l.o.lashley@lumc.nl. To gain access, data requestors will need to sign a data access agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No